These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 10868894)
1. Cotherapy with recombinant human IGF-I and insulin improves glycemic control in type 1 diabetes. Lanzetta P; Malara C Diabetes Care; 2000 Mar; 23(3):436-7. PubMed ID: 10868894 [No Abstract] [Full Text] [Related]
2. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Thrailkill KM; Quattrin T; Baker L; Kuntze JE; Compton PG; Martha PM Diabetes Care; 1999 Apr; 22(4):585-92. PubMed ID: 10189536 [TBL] [Abstract][Full Text] [Related]
3. Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications? Møller N; Orskov H Lancet; 1997 Oct; 350(9086):1188-9. PubMed ID: 9652553 [No Abstract] [Full Text] [Related]
10. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes? Dunger DB; Acerini CL Diabet Med; 1997 Sep; 14(9):723-31. PubMed ID: 9300221 [TBL] [Abstract][Full Text] [Related]
11. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Clemmons DR Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015 [TBL] [Abstract][Full Text] [Related]
12. Does recombinant human insulin-like growth factor I have a role in the treatment of type I (insulin dependent) diabetes during puberty? Dunger DB; Cheetham TD J Pediatr Endocrinol Metab; 1995; 8(4):237-42. PubMed ID: 8821899 [No Abstract] [Full Text] [Related]
13. The therapeutic potential of recombinant human insulin-like growth factor-I. Cotterill AM Clin Endocrinol (Oxf); 1992 Jul; 37(1):11-5. PubMed ID: 1424187 [No Abstract] [Full Text] [Related]
14. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Jabri N; Schalch DS; Schwartz SL; Fischer JS; Kipnes MS; Radnik BJ; Turman NJ; Marcsisin VS; Guler HP Diabetes; 1994 Mar; 43(3):369-74. PubMed ID: 8314009 [TBL] [Abstract][Full Text] [Related]
15. Management of insulin-dependent diabetes: hypoglycaemia and the eye. Frier BM Eye (Lond); 1993; 7 ( Pt 2)():293-7. PubMed ID: 7607349 [No Abstract] [Full Text] [Related]
17. High dose intravenous, but not low dose subcutaneous, insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus. Usala AL; Madigan T; Burguera B; Cefalu W; Sinha MK; Powell JG; Usala SJ J Clin Endocrinol Metab; 1994 Aug; 79(2):435-40. PubMed ID: 8045959 [TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-I for the treatment of type 1 diabetes. Acerini CL; Dunger DB Diabetes Obes Metab; 2000 Dec; 2(6):335-43. PubMed ID: 11225962 [No Abstract] [Full Text] [Related]
19. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes. Clemmons DR; Sleevi M; Allan G; Sommer A J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090 [TBL] [Abstract][Full Text] [Related]
20. Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. Bereket A; Lang CH; Blethen SL; Gelato MC; Fan J; Frost RA; Wilson TA J Clin Endocrinol Metab; 1995 Apr; 80(4):1312-7. PubMed ID: 7536205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]